Trial Profile
A phase II study to demonstrate the efficacy of GC021109 in patients with Alzheimer's disease .
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs GC 021109 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 16 Dec 2015 New trial record